Akari Therapeutics ADR (AKTX)

$1.11 +0.02 (1.85%)
Market Cap 35.07M
Revenue (ttm) 0.00
Net Income (ttm) -19.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.03
Volume 16,800
Avg Vol 20,234
Day's Range N/A - N/A
Shares Out 32.18M
Stochastic %K 33%
Beta 0.21
Analysts Strong Buy
Price Target $7.00

Company Profile

Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads in...

Industry: Biotechnology
Sector: Healthcare
Phone: 929 274 7510
Fax: 929 274 7553
Address:
22 Boston Wharf Road, Floor 7, Boston, United States
StockTwitsNinja
StockTwitsNinja Jul. 15 at 3:17 PM
$AKTX Slow bleed every single day and it will go below 1 when stock market is at all time high. No update from new CEO. I imagine, who would they hire next year
0 · Reply
MTN
MTN Jul. 11 at 4:20 AM
$AKTX https://virtualinvestorco.com/aktx/
0 · Reply
MTN
MTN Jul. 11 at 4:20 AM
$AKTX https://akaritx.com/2025/06/25/akari-therapeutics-releases-virtual-investor-what-this-means-segment-highlighting-its-recentlygranted-india-patent/
0 · Reply
StockTwitsNinja
StockTwitsNinja Jul. 9 at 5:05 PM
$AKTX Is this the worst performing stock ever or is it just auditioning for the part? Do we still have any brave investors hanging on or has everyone already jumped ship?
2 · Reply
dan16
dan16 Jun. 23 at 2:07 AM
$AKTX Looks like our new CEO got 246,428 shares as part of his coming on board. At least that's how I read it. But he did just buy 15,000 shares. Not a lot, but sill positive. https://www.nasdaq.com/market-activity/stocks/aktx/insider-activity
0 · Reply
Radek93
Radek93 Jun. 10 at 6:55 PM
$AKTX
0 · Reply
StockTwitsNinja
StockTwitsNinja Jun. 4 at 4:38 PM
$AKTX Why did I invest in this shit. WHY
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading May. 28 at 7:18 PM
⌛️⏳️ Potential swing ideas 💡 ✅️ $AKTX company specializing in the development of next-generation precision bi-functional antibody-drug conjugates (ADCs) for cancer treatment, lead candidate, AKTX-101, upcoming catalysts: 1) preclinical data presentation 2nd half 2025, 2) expanding preclinical studies to explore AKTX,101's's efficacy in various solid tumor indications, including prostate and lung cancers, 3) company exploring research collaborations, 4) participating in ASCO Annual Meeting from May 30 to June 3 in Chicago, 4) Live webinar on $BULL this Thursday 5/29 pm EST to discuss pipelines and upcoming catalysts ✅️ $SONM small float, recently announced new products set to launch in North America, EMEA, and Australia, 3 products in Q2 in North America, company is a leading US provider of rugged mobile solutions 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D
0 · Reply
coachmc
coachmc May. 16 at 11:42 PM
$AKTX absolute turd. Opportunities for a tech move up, but no news ever to reinforce it. Maybe next decade something will happen
1 · Reply
Teo_j
Teo_j May. 5 at 4:00 PM
$AKTX get ready
1 · Reply
Latest News on AKTX
Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent

Jun 25, 2025, 9:00 AM EDT - 21 days ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

Jun 18, 2025, 8:50 AM EDT - 4 weeks ago

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

May 29, 2025, 9:15 AM EDT - 6 weeks ago

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

May 22, 2025, 9:00 AM EDT - 7 weeks ago

Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

May 19, 2025, 8:00 AM EDT - 2 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

CRBP QURE

Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025, 8:05 AM EDT - 2 months ago

Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

May 1, 2025, 8:45 AM EDT - 2 months ago

Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

Apr 22, 2025, 9:05 AM EDT - 3 months ago

Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

Mar 20, 2025, 8:35 AM EDT - 4 months ago

Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules

Mar 3, 2025, 9:00 AM EST - 4 months ago

Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules

Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 5 months ago

Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Akari Therapeutics Joins Webull Corporate Connect Service Platform

Feb 3, 2025, 8:00 AM EST - 5 months ago

Akari Therapeutics Joins Webull Corporate Connect Service Platform

Akari Therapeutics Announces Key Leadership Appointments

Dec 18, 2024, 8:51 AM EST - 7 months ago

Akari Therapeutics Announces Key Leadership Appointments

Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

Dec 16, 2024, 9:05 AM EST - 7 months ago

Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

Nov 14, 2024, 4:15 PM EST - 8 months ago

Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

Nov 8, 2024, 8:00 AM EST - 8 months ago

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

Aug 19, 2024, 4:15 PM EDT - 11 months ago

Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

Aug 19, 2024, 8:00 AM EDT - 11 months ago

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

May 16, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics

May 1, 2024, 8:01 AM EDT - 1 year ago

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

May 1, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024

Apr 15, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

Apr 1, 2024, 6:30 AM EDT - 1 year ago

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Mar 5, 2024, 8:00 AM EST - 1 year ago

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing

Jan 2, 2024, 8:00 AM EST - 1 year ago

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing

Akari Therapeutics to Present at Biotech Showcase 2024

Dec 14, 2023, 8:00 AM EST - 1 year ago

Akari Therapeutics to Present at Biotech Showcase 2024

Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D.

Dec 1, 2023, 8:00 AM EST - 1 year ago

Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D.

Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Nov 16, 2023, 8:00 AM EST - 1 year ago

Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Nov 6, 2023, 8:00 AM EST - 1 year ago

Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

Sep 29, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

Akari Therapeutics to Present at Emerging Growth Conference

Sep 27, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics to Present at Emerging Growth Conference

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit

Sep 21, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit

Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs

Sep 19, 2023, 8:00 AM EDT - 1 year ago

Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs

Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials

Aug 18, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials

Akari Therapeutics, Plc Announces ADS Ratio Change

Aug 15, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics, Plc Announces ADS Ratio Change

Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs

Aug 2, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs

Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation

Jul 27, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation

Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer

Jul 19, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer

Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA

Jul 13, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA

Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy

Jul 11, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy

Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation

Jul 6, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation

Akari Therapeutics Appoints Industry Veteran Wa'el Hashad to Board of Directors

Jul 5, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Appoints Industry Veteran Wa'el Hashad to Board of Directors

Akari Therapeutics to Participate in A.G.P.'s Virtual Healthcare Conference

May 16, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics to Participate in A.G.P.'s Virtual Healthcare Conference

Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights

May 1, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights

Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement

Apr 25, 2023, 4:15 PM EDT - 2 years ago

Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement

Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs

Apr 14, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs

Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology

Apr 11, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology

Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting

Apr 3, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting

StockTwitsNinja
StockTwitsNinja Jul. 15 at 3:17 PM
$AKTX Slow bleed every single day and it will go below 1 when stock market is at all time high. No update from new CEO. I imagine, who would they hire next year
0 · Reply
MTN
MTN Jul. 11 at 4:20 AM
$AKTX https://virtualinvestorco.com/aktx/
0 · Reply
MTN
MTN Jul. 11 at 4:20 AM
$AKTX https://akaritx.com/2025/06/25/akari-therapeutics-releases-virtual-investor-what-this-means-segment-highlighting-its-recentlygranted-india-patent/
0 · Reply
StockTwitsNinja
StockTwitsNinja Jul. 9 at 5:05 PM
$AKTX Is this the worst performing stock ever or is it just auditioning for the part? Do we still have any brave investors hanging on or has everyone already jumped ship?
2 · Reply
dan16
dan16 Jun. 23 at 2:07 AM
$AKTX Looks like our new CEO got 246,428 shares as part of his coming on board. At least that's how I read it. But he did just buy 15,000 shares. Not a lot, but sill positive. https://www.nasdaq.com/market-activity/stocks/aktx/insider-activity
0 · Reply
Radek93
Radek93 Jun. 10 at 6:55 PM
$AKTX
0 · Reply
StockTwitsNinja
StockTwitsNinja Jun. 4 at 4:38 PM
$AKTX Why did I invest in this shit. WHY
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading May. 28 at 7:18 PM
⌛️⏳️ Potential swing ideas 💡 ✅️ $AKTX company specializing in the development of next-generation precision bi-functional antibody-drug conjugates (ADCs) for cancer treatment, lead candidate, AKTX-101, upcoming catalysts: 1) preclinical data presentation 2nd half 2025, 2) expanding preclinical studies to explore AKTX,101's's efficacy in various solid tumor indications, including prostate and lung cancers, 3) company exploring research collaborations, 4) participating in ASCO Annual Meeting from May 30 to June 3 in Chicago, 4) Live webinar on $BULL this Thursday 5/29 pm EST to discuss pipelines and upcoming catalysts ✅️ $SONM small float, recently announced new products set to launch in North America, EMEA, and Australia, 3 products in Q2 in North America, company is a leading US provider of rugged mobile solutions 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D
0 · Reply
coachmc
coachmc May. 16 at 11:42 PM
$AKTX absolute turd. Opportunities for a tech move up, but no news ever to reinforce it. Maybe next decade something will happen
1 · Reply
Teo_j
Teo_j May. 5 at 4:00 PM
$AKTX get ready
1 · Reply
coachmc
coachmc May. 5 at 2:51 PM
$AKTX golden cross??
1 · Reply
StockTwitsNinja
StockTwitsNinja Apr. 29 at 4:19 PM
$AKTX
0 · Reply
MTN
MTN Apr. 23 at 9:30 PM
$AKTX if they can close a proper partnership, looking at a strong valuation to push the company forward. I'm hoping they really are hyper focused on closing on one indication. That will allow them to start thinking bigger on other parts of the pipeline.
0 · Reply
jennybaby
jennybaby Apr. 23 at 3:31 PM
$AKTX good volume the last couple of days. Now let’s break $1.53 and never look back!
1 · Reply
dan16
dan16 Apr. 22 at 7:23 PM
$AKTX https://www.akaritx.com/2025/04/22/welcome-from-abizer-gaslightwala-president-and-ceo/
0 · Reply
dan16
dan16 Apr. 22 at 6:58 PM
$AKTX new CEO as of yesterday. Maybe he's really on the ball or did some pre-work. Wishful thinking.
0 · Reply
Bart69
Bart69 Apr. 22 at 6:41 PM
$AKTX Well, thanks for "looking out for us" and halted the F stock on the upswing.
0 · Reply
dartgator
dartgator Apr. 22 at 6:37 PM
$AKTX hmm what was that all about?
0 · Reply
Nick1971
Nick1971 Apr. 22 at 6:32 PM
$AKTX it’s now suspended on WeBull
0 · Reply
Bart69
Bart69 Apr. 22 at 6:30 PM
$AKTX Oh boy. Hopefully big news.
0 · Reply
HaltTradeAlert
HaltTradeAlert Apr. 22 at 6:29 PM
$AKTX Halt Time: 14:26:45 Issue Symbol: AKTX Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
StockTwitsNinja
StockTwitsNinja Apr. 22 at 6:29 PM
$AKTX I like this spike. Take it to 5
0 · Reply